ADVANCE OUTCOMES presentations include an analysis showing that ralinepag achieved clinical improvement in a lower risk pulmonary arterial hypertension (PAH) population and reduced clinical worsening in PAH patients with connective tissue disease, in which underlying vascular remodeling and endothelial dysfunction may be accelerated, making PAH more difficult to treat

TETON presentations include analyses showing that nebulized treprostinil improved lung function, demonstrated a consistent benefit in reducing serious clinical worsening events, and showed a dose-dependent magnitude of benefit compared to placebo in idiopathic pulmonary fibrosis (IPF) patients

Additional presentations feature interim data from the ARTISAN study of parenteral treprostinil in PAH patients and preliminary data from PHINDER, a first of its kind study designed to improve screening for pulmonary hypertension associated with interstitial lung disease (PH-ILD)

United Therapeutics Corporation (Nasdaq: UTHR), a public benefit corporation, today announced that four oral presentations and four poster presentations will be presented across its commercial and development portfolio at the European Society of Cardiology (ESC) Congress 2026, August 28-31 in Munich, and at the European Respiratory Society (ERS) Congress 2026, September 5-9 in Barcelona.

The presentations include late-breaking analyses from the phase 3 ADVANCE OUTCOMES study of investigational ralinepag in PAH, the phase 3 TETON clinical program evaluating nebulized treprostinil in IPF, and the ARTISAN study evaluating parenteral treprostinil in PAH, as well as preliminary data from the PHINDER study in PH-ILD.